Product Description
Mechanisms of Action: Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Ophthalmic
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genaera
Company Location: PLYMOUTH MEETING PA 19462
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Choroidal Neovascularization|Wet Macular Degeneration|Macular Degeneration
Phase 2: Macular Degeneration|Diabetic Retinopathy|Macular Edema|Wet Macular Degeneration|Prostate Cancer|Ovarian Cancer|Retinal Neovascularization|Choroidal Neovascularization|Retinal Vein Occlusion
Phase 1: Amyotrophic Lateral Sclerosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12619000375156 |
ACTRN12619000375156 | P1 |
Completed |
Amyotrophic Lateral Sclerosis |
2018-11-06 |
2024-08-29 |
Treatments |
|
NCT02511613 |
OHR-1501 | P2 |
Withdrawn |
Wet Macular Degeneration |
2016-04-01 |
2019-03-20 |
Treatments |
|
NCT02349516 |
Ohr-005 | P2 |
Withdrawn |
Macular Edema|Diabetic Retinopathy |
2015-09-01 |
2019-03-20 |
||
NCT01678963 |
OHR-002 | P2 |
Completed |
Wet Macular Degeneration |
2015-03-01 |
2019-03-19 |
Treatments |
|
NCT02614937 |
OHR-004 | P2 |
Completed |
Retinal Vein Occlusion|Macular Edema |
2014-12-01 |
2019-03-20 |
Treatments |
|
NCT01769183 |
Ohr-003 | P2 |
Completed |
Retinal Neovascularization|Diabetic Retinopathy |
2014-08-01 |
2019-03-19 |
Treatments |
|
NCT00244920 |
CDR0000446087 | P2 |
Withdrawn |
Prostate Cancer |
2007-06-01 |
2019-03-21 |
Treatments |
|
NCT00094120 |
MSI-1256F-208 | P2 |
Terminated |
Macular Degeneration |
2007-02-01 |
2019-03-21 |
Treatments |
|
NCT00021385 |
CDR0000068774 | P2 |
Unknown status |
Ovarian Cancer |
None |
2019-03-21 |
||
NCT00089830 |
MSI-1256F-209 | P2 |
Terminated |
Macular Degeneration |
None |
2019-03-21 |
Treatments |
|
NCT00333476 |
MSI-1256F-212 | P2 |
Terminated |
Choroidal Neovascularization|Macular Degeneration |
None |
2019-03-21 |
Treatments |
|
NCT02727881 |
MAKO | P3 |
Unknown status |
Macular Degeneration |
2017-12-01 |
2019-04-03 |
Treatments|Trial Status |
|
2005-001235-30 |
2005-001235-30 | P3 |
Active, not recruiting |
Choroidal Neovascularization|Macular Degeneration |
2008-03-07 |
2022-03-12 |
Treatments |
|
NCT00139282 |
MSI-1256F-301 | P3 |
Terminated |
Choroidal Neovascularization|Wet Macular Degeneration |
None |
2019-03-21 |
Treatments |